Ownership and insider activity for Acumen Pharmaceuticals, Inc. (ABOS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate.
Price
| Price | $2.61 |
| Market Cap | $189M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-15 | Porter Derrell | M-Exempt | 6,460 | $7K |
| 2026-06-17 | Porter Derrell | M-Exempt | 13,040 | $14K |
| 2026-06-15 | Porter Derrell | S-Sale | 6,460 | $15K |
| 2026-06-16 | Porter Derrell | S-Sale | 12,800 | $30K |
| 2026-06-17 | Porter Derrell | S-Sale | 13,040 | $30K |
| 2026-06-15 | Porter Derrell | M-Exempt | 6,460 | $7K |
| 2026-06-17 | Porter Derrell | M-Exempt | 13,040 | $14K |
| 2026-06-09 | Fountain Nathan B | S-Sale | 6,400 | $14K |
| 2026-06-03 | RA CAPITAL MANAGEMENT, L.P. | A-Award | 53,250 | $122K |
| 2026-06-03 | RA CAPITAL MANAGEMENT, L.P. | A-Award | 35,500 |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.6M | $43.8M | $122.2M | $130.1M | $66.9M | $35.6M | $54.0M |
| Short-term Investments | 0 | 0 | $72.1M | $47.5M | $176.6M | $135.9M | $62.9M |
| Receivables | $30000 | $109000 | 0 | 0 | $225000 | 0 | $625000 |
| Inventory | 0 | 0 | 0 | $199000 | 0 | $159000 | 0 |
| Total Current Assets | $7.2M | $44.4M | $198.7M | $180.3M | $246.6M | $178.3M | $122.3M |
| Property, Plant & Equipment | 0 | 0 | $36000 | $270000 | $503000 | $339000 | $243000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | $169000 | 0 | $29000 |
| Total Assets | $7.3M | $44.4M | $230.3M | $196.6M | $310.1M | $239.0M | $122.8M |
| Accounts Payable | $223000 | $531000 | $1.1M | $1.6M | $1.4M | $5.6M | $554000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $8.8M |
| Total Current Liabilities | $1.3M | $6.4M | $5.1M | $7.8M | $13.0M | $27.6M | $30.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | $27.3M | $29.4M | $22.4M |
| Total Liabilities | $18.7M | $63.0M | $5.1M | $7.8M | $43.2M | $57.2M | $52.4M |
| Retained Earnings | -$19.6M | -$27.0M | -$127.6M | -$170.4M | -$222.8M | -$325.1M | -$446.5M |
| Total Equity | -$11.4M | -$18.6M | $225.2M | $188.8M | $267.0M | $181.8M | $70.4M |
| Total Debt | 0 | 0 | 0 | $105000 | $28.5M | $29.7M | $31.3M |
| Net Debt | -$6.6M | -$43.8M | -$194.2M | -$177.5M | -$215.0M | -$141.9M | -$85.6M |
| Working Capital | $5.8M | $38.1M | $193.5M | $172.5M | $233.6M | $150.7M | $92.2M |
Financial Health
| Debt / Equity | 0.55 |
| Current Ratio | 2.47 |
Profitability
| Return on Equity | -136.27% |
| Return on Invested Capital | -118.57% |
| Return on Assets | -90.55% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACTU · AGEN · ALEC · FATE · INO · IRD · MCRB
Explore sector: Healthcare · Biotechnology
More sections of ABOS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks